JPMorgan Chase & Co. Takes $880,000 Position in CeriBell (NASDAQ:CBLL)

JPMorgan Chase & Co. acquired a new stake in shares of CeriBell (NASDAQ:CBLL) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 34,013 shares of the company’s stock, valued at approximately $880,000. JPMorgan Chase & Co. owned 0.09% of CeriBell as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in CBLL. Rhumbline Advisers bought a new stake in shares of CeriBell in the fourth quarter worth $320,000. Bank of New York Mellon Corp acquired a new position in shares of CeriBell during the fourth quarter valued at $628,000. Charles Schwab Investment Management Inc. bought a new stake in shares of CeriBell during the fourth quarter valued at about $2,500,000. PNC Financial Services Group Inc. bought a new stake in shares of CeriBell during the fourth quarter valued at about $47,000. Finally, Vanguard Group Inc. bought a new position in shares of CeriBell during the 4th quarter valued at about $18,015,000.

Insider Activity

In other news, CEO Xingjuan Chao sold 5,700 shares of the company’s stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $15.02, for a total transaction of $85,614.00. Following the completion of the transaction, the chief executive officer now owns 746,451 shares of the company’s stock, valued at approximately $11,211,694.02. This represents a 0.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders sold 24,700 shares of company stock valued at $372,434.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on CBLL shares. Canaccord Genuity Group restated a “buy” rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a report on Friday, April 4th. They set a “buy” rating and a $32.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, CeriBell has a consensus rating of “Buy” and a consensus price target of $32.50.

CeriBell Price Performance

Shares of NASDAQ:CBLL opened at $16.19 on Tuesday. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75. The stock has a fifty day simple moving average of $19.52.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analysts’ expectations of $17.55 million. As a group, equities analysts anticipate that CeriBell will post -2.46 EPS for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.